Sulfasalazine-induced immune thrombocytopenia. Issue 980 (5th June 2007)

• Record Type: Journal Article
• Authors: Cantarini, L; Tinazzi, I; Biasi, D; Fioravanti, A; Galeazzi, M
• Is Part Of: Postgraduate medical journal. Volume 83:Issue 980(2007)
• Page Start: e1
• Page End: e1
• Publication Date: 2007-06-05
• Subjects: NSAIDs, non-steroidal, anti-inflammatory drugs -- SLE, systemic lupus erythematosus -- TNFα, tumour necrosis factor α; Medicine -- Periodicals; 610
• DOI: 10.1136/pgmj.2006.055194
• Languages: English
• ISSNs: 0032-5473

Abstract

Abstract : Sulfasalazine is a well established disease-modifying anti-rheumatic drug commonly used in the treatment of rheumatic disorders and inflammatory bowel disease. Sulfasalazine was generally well tolerated in clinical trials, the most frequently reported adverse effects being adverse gastrointestinal effects, headache, dizziness and rash; myelosuppression can also occur. We are now reporting the first case of autoimmune thrombocytosis following sulfasalazine treatment.